Arovella Therapeutics Limited

ALA

AU0000182784

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:52 17/07/2024 BST			5-day change	1st Jan Change
0.165 ^AUD	+6.45%		+17.86%	+43.48%

07-04	Arovella Therapeutics Limited announced a financing transaction	CI
06-13	Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement	MT

Arovella Therapeutics Limited announced a financing transaction

July 03, 2024

Arovella Therapeutics Limited announced a private placement that it will issue 719,424 common shares to receive funding on July 4, 2024.

Latest news about Arovella Therapeutics Limited

Arovella Therapeutics Limited announced a financing transaction	07-03	CI
Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement	06-13	MT
Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9%	06-05	MT
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	03-26	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	03-20	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License	01-30	MT
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%	01-02	MT
Arovella Therapeutics Ltd. Announces Change of Company Address	12-06	CI
Arovella Therapeutics Appoints CFO	12-01	MT
Arovella Therapeutics Limited Announces Changes to its Board	12-01	CI
Arovella Therapeutics Limited Announces Executive Changes	12-01	CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	11-20	MT
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady	12/10/23	MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	12/10/23	MT
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director	07/09/23	CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan	11/07/23	MT
Arovella Therapeutics Extends Closing Date of Share Purchase Plan	29/06/23	MT
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance	26/06/23	MT
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan	07/06/23	MT
Arovella Therapeutics Completes Closure of Perth R&D Facility	01/05/23	MT
Arovella Therapeutics Appoints Nonexecutive Chair	13/03/23	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23	CI
Arovella, Imugene's Collaboration on Tumor Cells Therapy Progresses to Next Phase	10/02/23	MT

Chart Arovella Therapeutics Limited

Duration

Period

More charts

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROVELLA THERAPEUTICS LIMITED	+43.48%	110M
MODERNA, INC.	+25.83%	47.96B
IQVIA HOLDINGS INC.	+0.69%	42.45B
LONZA GROUP AG	+44.36%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research